A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
The eribulin, a microtubule-dynamics inhibitor was approved for specific subtypes of STS.
Eribulin demonstrated significantly better OS compared to dacarbazine in previously treated
patients with liposarcoma and leiomyosarcoma and approved as standard treatment. However, the
median progression free survival (PFS) and response rate (RR) was similar for both groups
which remains modest outcome of 2.6 months of PFS and 4% of RR. Therefore, to improve
antitumor activity, further combination strategy is strongly warranted. Based on the previous
studies, investigators suggest phase II trial of eribulin and gemcitabine combination in
previously treated patients with unresectable, advanced, or metastatic leiomyosarcoma or
liposarcoma.